Cargando…

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control

Myeloma is heterogeneous at the molecular level with subgroups of patients characterised by features of epigenetic dysregulation. Outcomes for myeloma patients have improved over the past few decades except for molecularly defined high-risk patients who continue to do badly. Novel therapeutic approa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pawlyn, C, Bright, M D, Buros, A F, Stein, C K, Walters, Z, Aronson, L I, Mirabella, F, Jones, J R, Kaiser, M F, Walker, B A, Jackson, G H, Clarke, P A, Bergsagel, P L, Workman, P, Chesi, M, Morgan, G J, Davies, F E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380911/ https://www.ncbi.nlm.nih.gov/pubmed/28362441 http://dx.doi.org/10.1038/bcj.2017.27

Ejemplares similares

MYC dysregulation in the progression of multiple myeloma
por: Misund, K, et al.
Publicado: (2019)

MMSET is the key molecular target in t(4;14) myeloma
por: Mirabella, F, et al.
Publicado: (2013)

Promiscuous Rearrangements of the MYC Locus Hijack Enhancers and Super-Enhancers to Dysregulate MYC Expression in Multiple Myeloma
por: Affer, Maurizio, et al.
Publicado: (2014)

The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma
por: Stein, Caleb K., et al.
Publicado: (2017)

Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application
por: Aronson, L I, et al.
Publicado: (2013)

UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression
por: Hussain, Sajjad, et al.
Publicado: (2015)

Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress()
por: Zhang, Lei, et al.
Publicado: (2013)

Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients
por: Walker, B A, et al.
Publicado: (2014)

Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma
por: Matthews, G M, et al.
Publicado: (2013)

Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?
por: Pawlyn, C, et al.
Publicado: (2016)

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
por: Rosenthal, A, et al.
Publicado: (2016)

A Novel Functional Role for MMSET in RNA Processing Based on the Link Between the REIIBP Isoform and Its Interaction with the SMN Complex
por: Mirabella, Fabio, et al.
Publicado: (2014)

Patient experience of whole body diffusion weighted magnetic resonance imaging (WB-MRI) for staging myeloma
por: Otero, S, et al.
Publicado: (2015)

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
por: Jones, J R, et al.
Publicado: (2016)

Molecular profiling in myeloma
por: Pawlyn, Charlotte, et al.
Publicado: (2018)

Clinical and Biological Implications of MYC Activation: A common difference between MGUS and newly diagnosed multiple myeloma
por: Chng, WJ, et al.
Publicado: (2011)

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
por: Shah, V, et al.
Publicado: (2018)

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
por: Davies, Faith E., et al.
Publicado: (2022)

Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplant
por: Meermeier, Erin W., et al.
Publicado: (2023)

Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial
por: Pawlyn, Charlotte, et al.
Publicado: (2020)

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma
por: Ravi, P, et al.
Publicado: (2017)

Dysregulated Recruitment of the Histone Methyltransferase EZH2 to the Class II Transactivator (CIITA) Promoter IV in Breast Cancer Cells
por: Truax, Agnieszka D., et al.
Publicado: (2012)

Alpha-synuclein overexpression induces epigenomic dysregulation of glutamate signaling and locomotor pathways
por: Schaffner, Samantha L, et al.
Publicado: (2022)

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma
por: Ravi, P, et al.
Publicado: (2016)

Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression
por: Croucher, Danielle C., et al.
Publicado: (2021)

Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target
por: Cao, Jinfeng, et al.
Publicado: (2018)

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study
por: Cook, Gordon, et al.
Publicado: (2019)

Identification of PIKfyve kinase as a target in multiple myeloma
por: de Campos, Cecilia Bonolo, et al.
Publicado: (2020)

P1262: EZH2 INHIBITORS MEDIATE PLATINUM RESISTANCE BY ENHANCED EFFLUX
por: Groß, E., et al.
Publicado: (2022)

EZH2 overexpression is associated with poor prognosis in patients with glioma
por: Zhang, Yanyang, et al.
Publicado: (2016)

Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients
por: Panopoulou, Aikaterini, et al.
Publicado: (2023)

Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
por: Bird, Sarah A., et al.
Publicado: (2020)

Dysregulated lipid metabolism blunts the sensitivity of cancer cells to EZH2 inhibitor
por: Zhang, Tengrui, et al.
Publicado: (2022)

Targeting EZH2 in Multiple Myeloma—Multifaceted Anti-Tumor Activity
por: Alzrigat, Mohammad, et al.
Publicado: (2018)

Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98
por: Alajez, N M, et al.
Publicado: (2010)

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
por: Walker, Brian A, et al.
Publicado: (2015)

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
por: Jones, John R., et al.
Publicado: (2023)

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
por: Kumar, S K, et al.
Publicado: (2015)

EZH2 alterations in follicular lymphoma: biological and clinical correlations
por: Huet, S, et al.
Publicado: (2017)

A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients.
por: Belch, A., et al.
Publicado: (1988)

Cannot write session to /tmp/vufind_sessions/sess_dprkfmsntr05b5076l709n8s7p